In support of a role for aberrant Wnt signaling during t-NEPC, TCF4 has also been shown to induce enzalutamide resistance via neuroendocrine differentiation in prostate cancer [61], and interestingly, FOXB2-Wnt7B signaling and Wnt11 are also reported to induce neuroendocrine differentiation and neuroendocrine marker expression in prostate cancer cells [62,63]. This evidence concerns the gene WNT7B and prostate carcinoma.